IRIS
MOSCARELLA, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.692
NA - Nord America 3.732
AS - Asia 2.329
SA - Sud America 396
Continente sconosciuto - Info sul continente non disponibili 183
AF - Africa 38
OC - Oceania 3
Totale 11.373
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.658
RU - Federazione Russa 3.381
SG - Singapore 834
CN - Cina 518
IE - Irlanda 409
VN - Vietnam 369
IT - Italia 362
BR - Brasile 324
HK - Hong Kong 324
GB - Regno Unito 152
DE - Germania 147
KR - Corea 92
IN - India 71
GR - Grecia 47
AR - Argentina 35
SE - Svezia 35
BD - Bangladesh 33
UA - Ucraina 31
CA - Canada 29
AT - Austria 25
FR - Francia 25
MX - Messico 25
TR - Turchia 20
FI - Finlandia 18
ID - Indonesia 16
BE - Belgio 14
CO - Colombia 10
NL - Olanda 10
MA - Marocco 9
ZA - Sudafrica 9
EC - Ecuador 8
ES - Italia 8
JP - Giappone 8
VE - Venezuela 8
IQ - Iraq 7
JM - Giamaica 6
KE - Kenya 6
PK - Pakistan 6
PL - Polonia 6
EG - Egitto 4
LT - Lituania 4
PH - Filippine 4
CL - Cile 3
EE - Estonia 3
IL - Israele 3
MY - Malesia 3
NP - Nepal 3
PR - Porto Rico 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AM - Armenia 2
BG - Bulgaria 2
BS - Bahamas 2
BY - Bielorussia 2
CR - Costa Rica 2
DK - Danimarca 2
HN - Honduras 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PY - Paraguay 2
RO - Romania 2
RS - Serbia 2
SA - Arabia Saudita 2
TN - Tunisia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
IR - Iran 1
JO - Giordania 1
LB - Libano 1
MU - Mauritius 1
NG - Nigeria 1
PS - Palestinian Territory 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
UG - Uganda 1
Totale 11.191
Salva come PNG Salva come JPEG
Città #
Moscow 1.206
San Jose 424
Singapore 414
Dublin 403
Santa Clara 329
Hong Kong 319
Ashburn 292
Council Bluffs 252
Chandler 212
New York 167
Ho Chi Minh City 128
Seoul 90
Hefei 84
Hanoi 71
Beijing 62
Milan 61
Bremen 60
Princeton 58
Roxbury 56
Los Angeles 55
Dallas 50
The Dalles 47
Jacksonville 45
Naples 45
Medford 43
Atlanta 33
Boardman 30
Bengaluru 29
Da Nang 27
Des Moines 25
São Paulo 25
Nuremberg 22
Rome 19
Falkenstein 18
Rio de Janeiro 18
Phoenix 16
San Francisco 16
Cambridge 15
Miano 15
Wilmington 15
Brussels 14
Caserta 14
Haiphong 14
Jinan 14
Kochi 14
Nanjing 14
Brasília 13
North Bergen 13
Hyderabad 11
Mexico City 11
Denver 10
Munich 10
Orem 10
Vienna 10
Ann Arbor 9
Hangzhou 9
Helsinki 9
Memphis 9
Thái Nguyên 9
Aversa 8
Belo Horizonte 8
Biên Hòa 8
Chicago 8
Frankfurt am Main 8
Guangzhou 8
Houston 8
Montreal 8
Ninh Bình 8
Sivas 8
Stockholm 8
Zhengzhou 8
Bologna 7
Brooklyn 7
London 7
Shenyang 7
Bari 6
Boston 6
Buffalo 6
Columbus 6
Hebei 6
Hải Dương 6
Johannesburg 6
Nairobi 6
Paris 6
Shenzhen 6
Bến Tre 5
Can Tho 5
Changsha 5
Curitiba 5
Dhaka 5
Ercolano 5
Joinville 5
Seattle 5
Shanghai 5
Tianjin 5
Toronto 5
Woodbridge 5
Bắc Ninh 4
Campinas 4
Casablanca 4
Totale 5.769
Salva come PNG Salva come JPEG
Nome #
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 282
Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study 276
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 275
Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. 273
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 270
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 269
Bioabsorbable drug-eluting vascular scaffold for the treatment of coronary in-stent restenosis: A two center registry 245
Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation? 238
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 184
Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy 176
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 174
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 171
Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study) 158
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 158
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 152
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 151
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 145
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 144
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 144
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 142
Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry) 142
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 142
Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis 141
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 141
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 135
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 133
Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry 133
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 131
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 130
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 129
Bioresorbable Vascular Scaffolds in In-Stent Restenosis 128
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. 123
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 118
Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management 117
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 116
Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry 116
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 114
Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) 113
Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis 111
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 111
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 109
Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Prospective RAI Registry) 108
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 108
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 108
Severely calcified coronary artery lesions: focus on interventional management 107
One-Year Clinical Outcomes After Unrestricted Implantation of Absorb Bioresorbable Scaffold (RAI Registry) 107
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 107
Alternative Approaches for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: The Call for a Personalized Treatment 105
Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial 103
Pathophysiology and Treatment of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: Focus on Low-Dose Fibrinolysis during Primary Percutaneous Intervention 101
Five-year clinical outcomes of STEMI patients treated with a pre-specified bioresorbable vascular scaffold implantation technique: Final results of the BVS STEMI STRATEGY-IT 101
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry 99
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome 98
IntravaScular Lithotripsy for the Management of UndILatable Coronary StEnt: The SMILE Registry 97
QFR for the Revascularization of Nonculprit Vessels in MI Patients: Insights From the FIRE Trial 96
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 96
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 96
Sudden cardiac death after early-onset myocardial infarction: a multicentre longitudinal cohort study with a 20-year follow-up 95
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 95
One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry 95
Multi-step percutaneous treatment of post-myocardial infarction ventricular septal defects: A case report and review of literature 95
Methods to assess bioresorbable vascular scaffold devices behaviour after implantation 94
Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial) 94
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 94
Latest STEMI treatment: a focus on current and upcoming devices 93
Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: Insights from five-year follow-up of the EXAMINATION trial 93
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 93
Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies 93
Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry 93
Management of high and intermediate-high risk pulmonary embolism: A position paper of the Interventional Cardiology Working Group of the Italian Society of Cardiology 90
Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA) 89
Sex-Related Differences in Long-Term Outcomes After Early-Onset Myocardial Infarction 89
Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy 89
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 86
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI) 85
Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation 85
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism 82
New percutaneous interventions in heart failure 80
Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience 79
Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis 78
In-stent restenosis because of nickel hypersensitivity: A bioresorbable solution? 78
Time for implementing high-sensitivity cardiac troponin assays in emergency departments in Italy 77
Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term 77
Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre registro absorb italiano (RAI registry) 76
Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium 76
First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis 75
Meta-Analysis Comparing Outcomes After Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients with Acute Coronary Syndromes 75
How should I treat a bioresorbable vascular scaffold edge restenosis and intra-scaffold dissection? 74
Letter regarding "hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI" 70
Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions 65
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 63
Antithrombotic therapy in complex percutaneous coronary intervention 42
Prognostic Impact of Bleeding in Interventional Cardiology 31
Correction to: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI) (Cardiovascular Diabetology, (2024), 23, 1, (420), 10.1186/s12933-024-02504-8) 28
Balloon-Expandable Myval Octacor Versus Self-Expanding Evolut PRO/PRO+ and Acurate Neo2: Short-Term Outcomes From Propensity-Matched Analysis 26
Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction: Three-Year Outcomes of a Randomized Clinical Trial 25
[GISE/ANMCO/SIC Consensus document on the implementation of the new recommendations for the use of coronary functional testing and intravascular imaging in coronary angioplasty for chronic coronary syndromes] 21
Prognostic impact of high-risk plaque morphology and impaired physiology in untreated non-culprit coronary lesions: a systematic review and meta-analysis 21
Global variability in bicuspid aortic valve morphology and aortopathy among patients with severe aortic stenosis referred for transcatheter valve implantation 17
Totale 11.373
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.361
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.361
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022380 0 0 0 17 121 9 5 31 8 27 28 134
2022/2023777 93 58 12 50 108 35 3 34 356 1 11 16
2023/2024465 20 8 9 11 99 137 27 0 3 17 21 113
2024/20251.293 2 21 5 49 194 156 190 122 165 199 118 72
2025/20266.049 215 282 334 326 479 3.162 329 328 248 185 94 67
2026/20272.053 190 906 525 432 0 0 0 0 0 0 0 0
Totale 11.373